Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc
Journal website

Case Report

Volume 12, Number 3, March 2021, pages 94-98

A Novel Report on the Compassionate Use of Baricitinib in Treating a Pediatric Patient With Severe Symptoms of COVID-19 Infection


Figure 1.
Figure 1. Series of chest X-ray images from the day of admission to the last day of admission. (a) Retrocardiac consolidation and patchy infiltrate in the left upper to mid lung fields and patchy infiltrate in the right lung, suspicious for pneumonic infiltrate (day 1). (b) There are bilateral patchy infiltrates unchanged, with no pleural fluid, and no pneumothorax (day 3). (c) Markedly suboptimal depth of inspiration. Bilateral hazy to patchy pneumonic infiltrates persist, but mild improvement from previous study (day 5). (d) Shallow depth of inspiration, mild atelectasis in the right perihilar distribution, and lungs otherwise grossly clear (day 7).
Figure 2.
Figure 2. Schematic diagram showing the inhibition of JAK/STAT by baricitinib. JAK/STAT: Janus kinase/signal transducer and activator transcription; COVID-19: coronavirus disease 2019.


Table 1. Markers of Inflammation Measured Daily From Admission to Discharge
CRP: C-reactive protein; ESR: erythrocyte sedimentation rate.
CRP (mg/mL)
ESR (mm/h)671269695-55
Ferritin (ng/mL)-251.2239.3215.2179.7-